Literature DB >> 1649660

Effects of tacrine, velnacrine (HP029), suronacrine (HP128), and 3,4-diaminopyridine on skeletal neuromuscular transmission in vitro.

M F Braga1, A L Harvey, E G Rowan.   

Abstract

1. The effects of tacrine (9-amino-1,2,3,4-tetrahydroacridine), velnacrine (HP029, 9-amino-1,2,3,4-tetrahydroacridin-1-ol maleate), suronacrine (HP128, 9-benzylamino-1,2,3,4-tetrahydroacridin-1-ol maleate), and 3,4-diaminopyridine on neuromuscular transmission were compared on isolated nerve-muscle preparations. 2. Tacrine, HP029, and 3,4-diaminopyridine augmented responses of chick biventer cervicis preparations to nerve stimulation, with tacrine and HP029 increasing responses to exogenously applied acetylcholine. HP128 blocked responses to nerve stimulation and to carbachol, but increased responses to acetylcholine. 3. In mouse diaphragm preparations that were partially paralysed by tubocurarine or low calcium solutions, tacrine, HP029, and 3,4-diaminopyridine reversed the twitch block. HP128 deepened the block. 4. In mouse triangularis sterni preparations, tacrine and HP029 prolonged the decay phase of endplate potentials and miniature endplate potentials, but had no effect on quantal content at 36 degrees C; above 10 microM, they reduced endplate potential amplitude. 3,4-Diaminopyridine increased quantal content without affecting the time course of the endplate potentials. HP128 (1-10 microM) had no effect on amplitude or time course of endplate potentials, but reduced their amplitude at higher concentrations. 5. Extracellular recording of nerve terminal currents from triangularis sterni preparations revealed that 3,4-diaminopyridine and HP128 had a selective blocking action on the waveform associated with K+ currents, tacrine reduced and prolonged the K(+)-related waveform, and HP029 had nonselective blocking actions only seen at high concentrations. 6. Tacrine and HP029 behave predominantly as anticholinesterase agents, while HP128 has weaker anticholinesterase actions that are masked by cholinoceptor blockade. Tacrine and HP128, but not HP029, have some blocking actions on K+ currents of mouse motor nerve terminals.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1649660      PMCID: PMC1917982          DOI: 10.1111/j.1476-5381.1991.tb12275.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Two different presynaptic calcium currents in mouse motor nerve terminals.

Authors:  R Penner; F Dreyer
Journal:  Pflugers Arch       Date:  1986-02       Impact factor: 3.657

2.  9-Amino-1,2,3,4-tetrahydroacridine (THA), an alleged drug for the treatment of Alzheimer's disease, inhibits acetylcholinesterase activity and slow outward K+ current.

Authors:  B Drukarch; K S Kits; E G Van der Meer; J C Lodder; J C Stoof
Journal:  Eur J Pharmacol       Date:  1987-09-02       Impact factor: 4.432

3.  Tetrahydroaminoacridine blocks voltage-dependent ion channels in hippocampal neurons.

Authors:  M A Rogawski
Journal:  Eur J Pharmacol       Date:  1987-10-06       Impact factor: 4.432

4.  Tetrahydroaminoacridine blocks potassium channels and inhibits sodium inactivation in Myxicola.

Authors:  C L Schauf; A Sattin
Journal:  J Pharmacol Exp Ther       Date:  1987-11       Impact factor: 4.030

5.  Effects of charybdotoxin, a blocker of Ca2+-activated K+ channels, on motor nerve terminals.

Authors:  A J Anderson; A L Harvey; E G Rowan; P N Strong
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

6.  Effects of THA on ionic currents in myelinated axons of Xenopus laevis.

Authors:  F Elinder; A K Mohammed; B Winblad; P Arhem
Journal:  Eur J Pharmacol       Date:  1989-05-30       Impact factor: 4.432

7.  9-Amino-1,2,3,4-tetrahydroacridine (THA) blocks agonist-induced potassium conductance in rat hippocampal neurones.

Authors:  J V Halliwell; E A Grove
Journal:  Eur J Pharmacol       Date:  1989-04-25       Impact factor: 4.432

8.  Excitatory actions of tetrahydro-9-aminoacridine (THA) on hippocampal pyramidal neurons.

Authors:  D R Stevens; C W Cotman
Journal:  Neurosci Lett       Date:  1987-08-31       Impact factor: 3.046

9.  Hepatotoxicity of tetrahydroaminoacridine.

Authors:  D J Ames; P S Bhathal; B M Davies; J R Fraser
Journal:  Lancet       Date:  1988-04-16       Impact factor: 79.321

10.  Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type.

Authors:  W K Summers; L V Majovski; G M Marsh; K Tachiki; A Kling
Journal:  N Engl J Med       Date:  1986-11-13       Impact factor: 91.245

View more
  8 in total

1.  Schwann cell nodal membrane disruption triggers bystander axonal degeneration in a Guillain-Barré syndrome mouse model.

Authors:  Rhona McGonigal; Clare I Campbell; Jennifer A Barrie; Denggao Yao; Madeleine E Cunningham; Colin L Crawford; Simon Rinaldi; Edward G Rowan; Hugh J Willison
Journal:  J Clin Invest       Date:  2022-07-15       Impact factor: 19.456

2.  Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

Authors:  K L Goa; A Fitton
Journal:  CNS Drugs       Date:  1994-03       Impact factor: 5.749

3.  Reversal by cysteine of the cadmium-induced block of skeletal neuromuscular transmission in vitro.

Authors:  M F Braga; E G Rowan
Journal:  Br J Pharmacol       Date:  1992-09       Impact factor: 8.739

4.  The effects of vesamicol on trains of endplate currents and on focally recorded nerve terminal currents at mammalian neuromuscular junctions.

Authors:  K E Pemberton; C Prior; I G Marshall
Journal:  Br J Pharmacol       Date:  1992-01       Impact factor: 8.739

5.  Apparent block of K+ currents in mouse motor nerve terminals by tetrodotoxin, mu-conotoxin and reduced external sodium.

Authors:  M F Braga; A J Anderson; A L Harvey; E G Rowan
Journal:  Br J Pharmacol       Date:  1992-05       Impact factor: 8.739

Review 6.  Tacrine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in Alzheimer's disease.

Authors:  A J Wagstaff; D McTavish
Journal:  Drugs Aging       Date:  1994-06       Impact factor: 3.923

7.  Update on treatment options for Lambert-Eaton myasthenic syndrome: focus on use of amifampridine.

Authors:  Sabine Lindquist; Martin Stangel
Journal:  Neuropsychiatr Dis Treat       Date:  2011-05-30       Impact factor: 2.570

8.  Glial Sulfatides and Neuronal Complex Gangliosides Are Functionally Interdependent in Maintaining Myelinating Axon Integrity.

Authors:  Rhona McGonigal; Jennifer A Barrie; Denggao Yao; Mark McLaughlin; Madeleine E Cunningham; Edward G Rowan; Hugh J Willison
Journal:  J Neurosci       Date:  2018-11-16       Impact factor: 6.167

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.